Literature DB >> 12746668

[Intravenous pulse methylprednisolone therapy for severe alopecia areata: an open study of 66 patients].

P Assouly1, P Reygagne, C Jouanique, B Matard, E Marechal, P Reynert, H Bachelez, L Dubertret.   

Abstract

INTRODUCTION: Treatment of alopecia areata is a difficult challenge. Some European publications have shown encouraging results with high dose pulse corticosteroid therapy in extensive plurifocal alopecia areata. We undertook a prospective open study between January 2000 and December 2001 using repeated pulse each month, with the aim of identifying the effects of this repetition and underlining the best indications. PATIENTS AND METHODS: Sixty-six patients aged 9 to 60 years old presenting an extensive alopecia areata exceeding 30% of the scalp surface (n=47), alopecia totalis (n=8), alopecia universalis (n=8), ophiasic alopecia (n=3), for less than 12 months entered this study. The administered treatment was methylprednisolone 500 mg/d during 3 days or 5 mg/kg twice per day during 3 days in children. These pulses were repeated after 4 and 8 weeks, then a second series was carried out or not according to cases. The main evaluation criterion was the percentage of new terminal hair appearing on the bald areas, appreciated by clinical and photographic evaluation at 3 and 6 months.
RESULTS: Ophiasic alopecia areata did not respond to treatment. A quarter of patients presenting universal alopecia had a good response (higher than 80 p. 100) followed by a relapse in half the cases. Half of the patients presenting alopecia totalis had a good response, which was maintained three times out of four. Multifocal alopecia areata seems the best indication since the patients under study presented a good response in 63.8 p. 100 of cases (78 p. 100 when it was a first episode and 90.5 p. 100 if the treatment had been started in less than 3 months before). The repetition of the pulses did not appear to increase the number of responders.
CONCLUSION: This study provides the best indication of pulse methylprednisolone therapy: first recent episode of extensive plurifocal alopecia areata. These results are less convincing in long term history or other forms of alopecia areata.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746668

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  5 in total

1.  Medium-dose prednisolone pulse therapy in alopecia areata.

Authors:  Pinelopi Efentaki; Andreas Altenburg; Johannes Haerting; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-11

2.  Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata.

Authors:  In Kwon Yeo; Eun Jung Ko; Yeon A No; Ee Seok Lim; Kui Young Park; Kapsok Li; Beom Joon Kim; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

3.  Rare Presentation of Alopecia Universalis Congenita and Twenty-nail Dystrophy in Siblings.

Authors:  Debdeep Mitra; Reetu Agarwal; Ajay Chopra; Renu Kandpal
Journal:  Int J Trichology       Date:  2017 Apr-Jun

4.  Combination therapy with cyclosporine and psoralen plus ultraviolet a in the patients with severe alopecia areata: a retrospective study with a self-controlled design.

Authors:  Kui Young Park; Woo Sun Jang; In Pyeong Son; Sun Young Choi; Moo Yeol Lee; Beom Joon Kim; Myeung Nam Kim; Byung In Ro
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

5.  Factors Associated with Severity of Alopecia Areata.

Authors:  Hye Rin You; Seong-Jin Kim
Journal:  Ann Dermatol       Date:  2017-08-25       Impact factor: 1.444

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.